Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for ALK-negative anaplastic large cell lymphoma, drawn from the whole corpus: 0 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Nothing recorded in development for this cancer yet.
The entity is defined by what it is not, and WHO-HAEM5 says so. Whether its genetic subgroups are real subtypes or prognostic markers is unresolved.
The prognostic meaning of DUSP22 rearrangement reversed between the first reports and the later ones, and treatment decisions have been made on the earlier version.
Autologous transplant consolidation in first remission is standard practice here on the strength of registry comparisons and a single-arm study, and has never been tested against continuing observation.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 7 changes by month →When this page itself was last checked or edited.
Brentuximab vedotin with cyclophosphamide, doxorubicin and prednisone, the same regimen as for ALK-positive disease and on the same trial: in ECHELON-2, five-year progression-free survival was 51.4 per cent against 43.0 with chemotherapy alone and overall survival 70.1 against 61.0. Consolidating a first remission with high-dose therapy and an autologous stem cell transplant is standard practice here, unlike in ALK-positive disease, and it rests on a single-arm study and registry comparisons rather than on a randomised trial; a patient is entitled to be told that. The regimens are on the peripheral T-cell lymphoma page.
CD30 and ALK immunohistochemistry on the biopsy. The diagnosis is partly a negative one: uniform strong CD30 with an anaplastic appearance and no ALK, in a lymphoma that is not confined to the skin and is not associated with a breast implant. Those two exclusions matter because both of them are treated very differently. Testing for DUSP22 and TP63 rearrangements is done where it is available, with the caution that WHO-HAEM5 does not regard the resulting groups as established subtypes.
WHO-HAEM5 states that there are not yet enough data to decide whether the genetic contexts are prognostic markers or molecular subtypes, and that the favourable outcome first reported for DUSP22 rearrangement has not been confirmed by more recent studies.
A+CHP improved progression-free and overall survival over CHOP in CD30-positive peripheral T-cell lymphoma; approved in November 2018.
Rearrangements of DUSP22 and TP63 were identified within ALK-negative disease and reported to carry very different outcomes, which raised the question of whether the entity should be split again.